FDA approves new indication for rosuvastatin
Links shared publicly online about this topic.
- 1,394total visits
FDA approves new indication for rosuvastatin
View full resource at endocrinetoday.com
Tags: Heart Disease, Cholesterol Medication, Heart Attack, Stroke, Thrombotic Event, FDA, Crestor
Most Recently Shared on February 9, 2010 at 4:07 pm By:
FDA approves new indication for rosuvastatin http://ow.ly/15uRc
ACP Hospitalist, March 2012 - Handheld hematoma scanner, new indication for pneumonia vaccine approved
acphospitalist.org — “ACP Hospitalist, March 2012 - Handheld hematoma scanner, new indication for pneumonia vaccine approved” View full resource at acphospitalist.org
Most Recently Shared on March 22, 2012 at 1:55 pm By:
#FDA approves handheld hematoma scanner, new indication for pneumonia vaccine http://t.co/SWtnWt3f #vaxfax
Bayer HealthCare receives FDA approval for Natazia to treat HMB
news-medical.net — “Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose an oral contraceptive (OC) for contraception.” View full resource at news-medical.net
Most Recently Shared on March 15, 2012 at 4:43 am By:
Bayer HealthCare receives FDA approval for Natazia to treat HMB: Bayer HealthCare Pharmaceuticals Inc. today ann... http://t.co/owLKhz1u
Crude Awakening: Mineral Oil Contaminates Everyone's Bodies | GreenMedInfo | Blog entry | Natural Medicine | Alternative Medicine | Integrative Medicine | Consumer Advocacy
greenmedinfo.com — “Greenmedinfo.com - Natural Medical Resource - The only website in the world that has free, entirely evidence-based, and solar-powered natural medical database with 18,000+ articles and growing daily” View full resource at greenmedinfo.com
Most Recently Shared on February 3, 2012 at 10:50 am By:
FDA allows Vytorin labeling for use in kidney disease, but not new indication
nephrologynews.com — “FDA did not approve a new indication for Vytorin or for Zetia” View full resource at nephrologynews.com
Most Recently Shared on January 27, 2012 at 3:56 pm By:
Nephrology News Health News and Nephrology
FDA allows Vytorin labeling for use in kidney disease, but not new indication http://t.co/oMlX4LMD
Medical News: FDA Okays Byetta Plus Insulin Glargine - in Public Health & Policy, FDA General from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA has approved a new indication for the type 2 diabetes drug exenatide (Byetta) as an add-on therapy with insulin glargine, diet, and exercise for adult patients.” View full resource at medpagetoday.com
Most Recently Shared on October 20, 2011 at 6:35 pm By:
FDA okays Byetta plus insulin glargine: http://t.co/SjJfiocG
New Indication for Exenatide : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on October 20, 2011 at 2:18 pm By:
Bob Finn - Medical News Net Health News
FDA: Exenatide (Byetta) approved for adults with type 2 diabetes as an add-on therapy to insulin glargine. http://t.co/DKg62KJu
Medical News: FDA Panel Vetoes New Indication for Parkinson's Drug - in Neurology, Parkinson's Disease from MedPage Today
medpagetoday.com — “SILVER SPRING, Md. -- An FDA advisory committee has voted 17 to 0 that Azilect (rasagiline), a drug that is already approved to treat symptoms of Parkinson's disease, does not work to slow progression” View full resource at medpagetoday.com
Most Recently Shared on October 18, 2011 at 12:31 am By:
FDA panel vetoes new indication for Parkinson's drug: http://t.co/NwONyZuA
FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy - MarketWatch
marketwatch.com — “FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on September 20, 2011 at 1:05 am By:
JanCerny, MD, PhD Hematologist, Physician, Doctor, PhD, Internist, and Oncologist
FDA Approves New Indications for Denosumab to Treat Bone Loss in Pts With Prostate or Breast CA on Hormonal Therapy http://ow.ly/6yY3i
FDA Approves New Indications for Prolia (denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
drugs.com — “Prolia (denosumab) is used in the treatment of bone loss in patients with prostate or breast cancer undergoing hormone ablation therapy. Includes Prolia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on September 20, 2011 at 1:04 am By:
Drugs and Devices OW OW Health
FDA Approves New Indications for Prolia (denosumab) for the Treatment of Bone Loss in Patients With Prosta... http://t.co/vescEIgy #drug
FDA Approves New Indications for Prolia (denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
drugs.com — “Prolia (denosumab) is used in the treatment of bone loss in patients with prostate or breast cancer undergoing hormone ablation therapy. Includes Prolia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on September 20, 2011 at 12:39 am By:
FDA Approves New Indications for Prolia (denosumab) for Cancer Treatment-Induced Bone Loss - http://t.co/f77E3osL
Bayer, J&J Blood Thinner Gets FDA Panel Backing For New Indication
rttnews.com — “Blood thinner Xarelto, co-developed by Bayer HealthCare, a subsidiary of German chemical and pharmaceutical giant Bayer AG (BYR.L) (BAYRY.PK) and Johnson & Johnson (JNJ) won an FDA expert panel vote Thursday, backing the approval of the drug for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in the U.” View full resource at rttnews.com
Most Recently Shared on September 9, 2011 at 12:28 pm By:
Drugs and Devices OW OW Health
Bayer, J&J Stroke Drug Gets FDA Panel Backing - RTT News: USA TodayBayer, J&J Stroke Drug Gets FDA Panel B... http://t.co/ruIUBoN #drug
FDA Reviewer Slams Xarelto for Stroke Prevention in Afib - QualityPoint Technologies
qualitypointtech.net — “WASHINGTON (MedPage Today) -- Rivaroxaban (Xarelto) is not as effective as warfarin for preventing strokes in patients with atrial fibrillation and should not be approved for the new indication, according to an FDA reviewer.” View full resource at qualitypointtech.net
Most Recently Shared on September 6, 2011 at 5:00 pm By:
FDA Reviewer Slams Xarelto for Stroke Prevention in Afib: WASHINGTON (MedPage Today) -- Rivaroxaban (Xarelto) is ... http://t.co/6bEwbRZ
Medical News: FDA Reviewer Slams Xarelto for Stroke Prevention in Afib - in Cardiovascular, Strokes from MedPage Today
medpagetoday.com — “WASHINGTON -- Rivaroxaban (Xarelto) is not as effective as warfarin for preventing strokes in patients with atrial fibrillation and should not be approved for the new indication, according to an FDA” View full resource at medpagetoday.com
Most Recently Shared on September 6, 2011 at 4:51 pm By:
HealthTrendster Health Executive
FDA Reviewer Slams Xarelto for Stroke Prevention in Afib: WASHINGTON (MedPage Today… http://t.co/knMi5wv
Medical News: FDA Reviewer Slams Xarelto for Stroke Prevention in Afib - in Cardiovascular, Strokes from MedPage Today
medpagetoday.com — “WASHINGTON -- Rivaroxaban (Xarelto) is not as effective as warfarin for preventing strokes in patients with atrial fibrillation and should not be approved for the new indication, according to an FDA” View full resource at medpagetoday.com
Most Recently Shared on September 6, 2011 at 4:49 pm By:
Patricia Grace Eldercare Expert
FDA Reviewer Slams Xarelto for Stroke Prevention in Afib: WASHINGTON (MedPage Today) -- Rivaroxaban (Xarelto) i... http://t.co/U0jTyUN
Medical News: FDA Reviewer Slams Xarelto for Stroke Prevention in Afib - in Cardiovascular, Strokes from MedPage Today
medpagetoday.com — “WASHINGTON -- Rivaroxaban (Xarelto) is not as effective as warfarin for preventing strokes in patients with atrial fibrillation and should not be approved for the new indication, according to an FDA” View full resource at medpagetoday.com
Most Recently Shared on September 6, 2011 at 4:11 pm By:
FDA reviewer slams Xarelto for stroke prevention in Afib: http://t.co/d4nW7Qp
Advertisement
